Cell Therapy for Vascular Wounds - Gut Microbiota Modulation as a Therapeutic

1. Advanced Cell Therapy Platform for Chronic Diabetic and Vascular Wounds (University Spin-off)

This innovative Italian life science spin-off is developing a regenerative medicine platform focused on chronic and hard-to-heal wounds (e.g., diabetic, vascular, oncologic). The founding team has over 20 years of clinical experience in wound care, plastic surgery, and microsurgery, and has participated in several EU projects.

The project targets chronic wounds, venous and arterial ulcers typical of diabetes, aiming to develop an innovative cell therapy.

The company is currently looking for:

· GMP-certified facilities for SVF cell production

· Hospitals/clinical centers for Phase III clinical trials

· OEMs or distributors for market access and scale-up

2. Gut Microbiota Modulation as a Therapeutic Strategy for Multiple Sclerosis (University Research Group)

This research group investigates the role of gut microbiota in the pathogenesis of Multiple Sclerosis, focusing on how specific microbial species and their metabolites influence immune system modulation. The objective is to identify microbial biomarkers and develop microbiota-based therapeutic strategies for autoimmune diseases.

The team is seeking partners with expertise in:

· Analysis of microbial metabolites (e.g., tryptophan derivatives, short-chain fatty acids) in biological samples

· Isolation and characterization of bacterial species for in vitro immune testing

· Food or supplement formulation for targeted delivery of microbiota-modifying compounds

In addition to promoting and supporting its members, the Cluster FVG can also join consortia directly and contribute to work packages related to dissemination, ecosystem building, training, stakeholder engagement, and clinical adoption pathways.